R.K. Gregory

1.1k total citations
19 papers, 874 citations indexed

About

R.K. Gregory is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, R.K. Gregory has authored 19 papers receiving a total of 874 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 6 papers in Cancer Research and 4 papers in Pathology and Forensic Medicine. Recurrent topics in R.K. Gregory's work include Breast Cancer Treatment Studies (6 papers), HER2/EGFR in Cancer Research (4 papers) and Estrogen and related hormone effects (3 papers). R.K. Gregory is often cited by papers focused on Breast Cancer Treatment Studies (6 papers), HER2/EGFR in Cancer Research (4 papers) and Estrogen and related hormone effects (3 papers). R.K. Gregory collaborates with scholars based in United Kingdom, United States and Canada. R.K. Gregory's co-authors include T.J. Powles, Mitch Dowsett, Andreas Makris, Jenny C. Chang, S. Ashley, L. Assersohn, D. Craig Allred, C. Kent Osborne, S. Ashley and Jian Chang and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

R.K. Gregory

19 papers receiving 843 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R.K. Gregory United Kingdom 13 564 410 213 208 132 19 874
Ulla Johansson Sweden 16 598 1.1× 493 1.2× 261 1.2× 272 1.3× 168 1.3× 21 1.1k
JFR Robertson United Kingdom 12 435 0.8× 333 0.8× 138 0.6× 327 1.6× 184 1.4× 13 830
S. Johnston United Kingdom 18 508 0.9× 262 0.6× 371 1.7× 265 1.3× 75 0.6× 50 923
G. T. Budd United States 11 710 1.3× 346 0.8× 327 1.5× 278 1.3× 80 0.6× 20 1.1k
Ermelinda De Maio Italy 16 533 0.9× 284 0.7× 217 1.0× 425 2.0× 92 0.7× 30 1.1k
Izo Kimijima Japan 16 330 0.6× 272 0.7× 158 0.7× 317 1.5× 150 1.1× 65 872
Catherine Andrieu France 10 434 0.8× 382 0.9× 141 0.7× 427 2.1× 68 0.5× 11 916
RD Rubens United Kingdom 8 436 0.8× 421 1.0× 128 0.6× 162 0.8× 63 0.5× 9 691
Hilary A. Chaudri‐Ross Switzerland 8 720 1.3× 689 1.7× 478 2.2× 133 0.6× 116 0.9× 9 1.0k
Eleanor Gutteridge United Kingdom 8 553 1.0× 200 0.5× 147 0.7× 214 1.0× 61 0.5× 27 800

Countries citing papers authored by R.K. Gregory

Since Specialization
Citations

This map shows the geographic impact of R.K. Gregory's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R.K. Gregory with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R.K. Gregory more than expected).

Fields of papers citing papers by R.K. Gregory

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R.K. Gregory. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R.K. Gregory. The network helps show where R.K. Gregory may publish in the future.

Co-authorship network of co-authors of R.K. Gregory

This figure shows the co-authorship network connecting the top 25 collaborators of R.K. Gregory. A scholar is included among the top collaborators of R.K. Gregory based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R.K. Gregory. R.K. Gregory is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Urruticoechea, Ander, Caroline Archer, L. Assersohn, et al.. (2005). Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer. British Journal of Cancer. 92(3). 475–479. 14 indexed citations
2.
Assersohn, L., Janine Salter, T.J. Powles, et al.. (2003). Studies of the Potential Utility of Ki67 as a Predictive Molecular Marker of Clinical Response in Primary Breast Cancer. Breast Cancer Research and Treatment. 82(2). 113–123. 54 indexed citations
3.
Mendes, R., Mary O’Brien, Abhishek Mitra, et al.. (2002). Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma. British Journal of Cancer. 86(3). 336–341. 18 indexed citations
4.
Gregory, R.K., Ian E. Smith, A. Norton, S. Ashley, & Mary O’Brien. (2001). Mitomycin C, Vinblastine and Carboplatin: Effective Outpatient Chemotherapy for Advanced Non-Small Cell Carcinoma of the Lung (NSCLC). Clinical Oncology. 13(6). 483–487. 2 indexed citations
5.
Gregory, R.K.. (2000). Investigating lymphadenopathy---report on the first 12 months of the lymph node diagnostic clinic at the Royal Marsden Hospital. Postgraduate Medical Journal. 76(899). 566–568. 4 indexed citations
6.
Gregory, R.K., T.J. Powles, Janine Salter, et al.. (2000). Prognostic relavance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy. Breast Cancer Research and Treatment. 59(2). 171–175. 29 indexed citations
7.
Gregory, R.K., et al.. (2000). True. British Journal of Cancer. 82(12). 1907–1913. 112 indexed citations
8.
Gregory, R.K., Mark Hill, J. Moore, et al.. (2000). Combining platinum, paclitaxel and anthracycline in patients with advanced gynaecological malignancy. European Journal of Cancer. 36(4). 503–507. 17 indexed citations
9.
Chang, Jenny C., T.J. Powles, D. Craig Allred, et al.. (2000). Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients.. PubMed. 6(2). 616–21. 90 indexed citations
10.
Dowsett, Mitch, Caroline Archer, L. Assersohn, et al.. (1999). Clinical studies of apoptosis and proliferation in breast cancer.. Endocrine Related Cancer. 6(1). 25–28. 46 indexed citations
11.
Chang, Jian, T.J. Powles, D. Craig Allred, et al.. (1999). Biologic Markers as Predictors of Clinical Outcome From Systemic Therapy for Primary Operable Breast Cancer. Journal of Clinical Oncology. 17(10). 3058–3063. 185 indexed citations
12.
Chang, Jenny H., T.J. Powles, S. Ashley, et al.. (1998). Variation in endometrial thickening in women with amenorrhea on tamoxifen. Breast Cancer Research and Treatment. 48(1). 81–85. 26 indexed citations
13.
Gregory, R.K., et al.. (1998). Systemic candidiasis with candida vasculitis due to Candida kruzei in a patient with acute myeloid leukaemia. Bone Marrow Transplantation. 23(1). 103–104. 7 indexed citations
14.
Gregory, R.K., T.J. Powles, Jenny C. Chang, & S. Ashley. (1997). A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast. European Journal of Cancer. 33(13). 2194–2197. 44 indexed citations
15.
Wille, G, R.K. Gregory, & James M. Guernsey. (1997). Tumor implantation at port site of video-assisted thoracoscopic resection of pulmonary metastasis.. PubMed. 166(1). 65–6. 11 indexed citations
16.
Makris, Andreas, T.J. Powles, Mitch Dowsett, et al.. (1997). Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas.. PubMed. 3(4). 593–600. 116 indexed citations
17.
Gregory, R.K., et al.. (1997). Leukaemic infiltration or primary carcinoma of the breast in a patient with acute myeloid leukaemia?. The Breast. 6(5). 303–305. 1 indexed citations
18.
19.
Gregory, R.K., et al.. (1996). Clubbing, arthralgia and haemoptysis in a patient with metastatic carcinoma of the breast. Annals of Oncology. 7(7). 756–757. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ulla Johansson Breakdown of academic impact, for papers by JFR Robertson Breakdown of academic impact, for papers by S. Johnston Breakdown of academic impact, for papers by G. T. Budd Breakdown of academic impact, for papers by Ermelinda De Maio Breakdown of academic impact, for papers by Izo Kimijima Breakdown of academic impact, for papers by Catherine Andrieu Breakdown of academic impact, for papers by RD Rubens Breakdown of academic impact, for papers by Hilary A. Chaudri‐Ross Breakdown of academic impact, for papers by Eleanor Gutteridge
Rankless by CCL
2026